Plasma alpha‐synuclein detected by single molecule array is increased in PD

We utilized ultrasensitive single molecule technology to measure plasma alpha‐synuclein in 221 subjects (51 controls, 170 PD). Plasma alpha‐synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD, alpha‐synuclein leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Adeline S. L., Tan, Yi Jayne, Lu, Zhonghao, Ng, Ebonne Y. L., Ng, Samuel Y. E., Chia, Nicole S. Y., Setiawan, Fiona, Xu, Zheyu, Tay, Kay Yaw, Prakash, Kumar M., Au, Wing Lok, Tan, Eng‐King, Tan, Louis C. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414476/
https://www.ncbi.nlm.nih.gov/pubmed/30911585
http://dx.doi.org/10.1002/acn3.729
Descripción
Sumario:We utilized ultrasensitive single molecule technology to measure plasma alpha‐synuclein in 221 subjects (51 controls, 170 PD). Plasma alpha‐synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD, alpha‐synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition (MMSE ≤ 25) than controls (P = 0.016, Bonferroni corrected P = 0.047). Alpha‐synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.

Ejemplares similares